These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 29758342)

  • 1. Next-generation sequencing in drug development: target identification and genetically stratified clinical trials.
    Doostparast Torshizi A; Wang K
    Drug Discov Today; 2018 Oct; 23(10):1776-1783. PubMed ID: 29758342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of drug response and adverse drug reactions: From twin studies to Next Generation Sequencing.
    Lauschke VM; Ingelman-Sundberg M
    Eur J Pharm Sci; 2019 Mar; 130():65-77. PubMed ID: 30684656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials.
    Hyman DM; Solit DB; Arcila ME; Cheng DT; Sabbatini P; Baselga J; Berger MF; Ladanyi M
    Drug Discov Today; 2015 Dec; 20(12):1422-8. PubMed ID: 26320725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NGS analysis on tumor tissue and cfDNA for genotype-directed therapy in metastatic NSCLC patients. Between hope and hype?
    Falk AT; Heeke S; Hofman V; Lespinet V; Ribeyre C; Bordone O; Poudenx M; Otto J; Garnier G; Castelnau O; Guigay J; Leroy S; Marquette CH; Hofman P; Ilié M
    Expert Rev Anticancer Ther; 2017 Aug; 17(8):681-685. PubMed ID: 28511612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ushering in the next generation of precision trials for pediatric cancer.
    DuBois SG; Corson LB; Stegmaier K; Janeway KA
    Science; 2019 Mar; 363(6432):1175-1181. PubMed ID: 30872517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the biomarker enrichment strategy in drug development.
    Lara Gongora AB; Carvalho Oliveira LJ; Jardim DL
    Expert Rev Mol Diagn; 2020 Jun; 20(6):611-618. PubMed ID: 31903795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Profiling in Drug Development: Paving a Way Forward.
    Jones SF; McKenzie AJ
    Am Soc Clin Oncol Educ Book; 2020 May; 40():309-318. PubMed ID: 32463698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapy according to next generation sequencing-based panel sequencing.
    Saito M; Momma T; Kono K
    Fukushima J Med Sci; 2018 Apr; 64(1):9-14. PubMed ID: 29628467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From next-generation sequencing to targeted treatment of non-acquired epilepsies.
    Møller RS; Hammer TB; Rubboli G; Lemke JR; Johannesen KM
    Expert Rev Mol Diagn; 2019 Mar; 19(3):217-228. PubMed ID: 30661434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification, Prioritization, and Treatment of Mutations Identified by Next-Generation Sequencing.
    Mansfield AS; Park BH; Mullane MP
    Am Soc Clin Oncol Educ Book; 2018 May; 38():873-880. PubMed ID: 30231389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
    Paolillo C; Londin E; Fortina P
    Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Applications of Next-Generation Sequencing.
    Rebollar-Vega RG; Arriaga-Canon C; de la Rosa-Velázquez IA
    Rev Invest Clin; 2018; 70(4):153-157. PubMed ID: 30067721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next-generation sequencing: hype and hope for development of personalized radiation therapy?
    Tinhofer I; Niehr F; Konschak R; Liebs S; Munz M; Stenzinger A; Weichert W; Keilholz U; Budach V
    Radiat Oncol; 2015 Aug; 10():183. PubMed ID: 26316159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the Oncomine
    Williams HL; Walsh K; Diamond A; Oniscu A; Deans ZC
    Virchows Arch; 2018 Oct; 473(4):489-503. PubMed ID: 30105577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of Targeted Therapies Based on Gene Modification.
    Benson TM; Leti F; DiStefano JK
    Methods Mol Biol; 2018; 1706():39-51. PubMed ID: 29423792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges Related to the Use of Next-Generation Sequencing for the Optimization of Drug Therapy.
    Zhou Y; Lauschke VM
    Handb Exp Pharmacol; 2023; 280():237-260. PubMed ID: 35792943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurology Individualized Medicine: When to Use Next-Generation Sequencing Panels.
    Klein CJ; Foroud TM
    Mayo Clin Proc; 2017 Feb; 92(2):292-305. PubMed ID: 28160876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience.
    Lih CJ; Takebe N
    Curr Probl Cancer; 2017; 41(3):201-211. PubMed ID: 28625332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Quality Considerations when Using Next-Generation Sequencing (NGS) in Clinical Drug Development.
    Ménard T; Barros A; Ganter C
    Ther Innov Regul Sci; 2021 Sep; 55(5):1066-1074. PubMed ID: 34046876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of high-throughput DNA sequencing to the study of primary immunodeficiencies.
    Picard C; Fischer A
    Eur J Immunol; 2014 Oct; 44(10):2854-61. PubMed ID: 25154746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.